Important Safety Information Do not use AOD-9604 if you: Have active cancer or malignancy (use only under medical supervision with appropriate monitoring) Are pregnant or breastfeeding (safety data lacking in these populations) Have known allergy to growth hormone fragments or peptide compounds Have severe uncontrolled metabolic or cardiovascular disease without medical supervision Common side effects may include: Injection site reactions (mild redness, swelling, or tenderness), occasional mild headaches during initial use, and transient lightheadedness
Injectable GHK-Cu: Systemic and faster-acting in published case reports and user diaries, but requires sterile technique and ideally physician oversight
Animal studies (Neelakantan et al., Biochemical Pharmacology, 2018) showed significant body fat reduction without changes in food intake
after reconstitution, refrigerate at 28 C (35.646.4 F) , protect from light, and use within 24 weeks
At standard dosing ranges of 200500 mcg daily, it supports lipolysis, fat oxidation, and reduced fat storage, while avoiding increases in IGF-1 or negative impacts on glucose metabolism
